

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/211860 A1

(51) International Patent Classification:

A61K 38/20 (2006.01) C07K 14/715 (2006.01)
A61P 35/00 (2006.01) C12N 15/62 (2006.01)
C07K 14/55 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(21) International Application Number:

PCT/US2021/027507

(22) International Filing Date:

15 April 2021 (15.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/010,185 15 April 2020 (15.04.2020) US

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(71) Applicants: ALKERMES PHARMA IRELAND

LIMITED [IE/IE]; One Burlington Road, Connaught
House, Dublin 4 (IE). CLOVIS ONCOLOGY, INC.
[US/US]; 5500 Flatiron Parkway, Suite 100, Boulder, Col-
orado 80301 (US).

(72) Inventors: LOPES, Jared; 9 Hillside Way, Wilming-

ton, Massachusetts 01887 (US). LOSEY, Heather, C.;
12 Taft Avenue, Lexington, Massachusetts 02421 (US).
WINQUIST, Raymond, J.; 196 Carolyn Circle, Marsh-
field, Massachusetts 02050 (US). DUSEK, Rachel; 1816
Oak Knoll Dr., Belmont, Massachusetts 94002 (US). SIM-
MONS, Andrew, David; 29 Plymouth Ave, San Carlos,
California 94070 (US).

(74) Agent: SPELLBERG, Michael et al.; Lathrop GPM LLP,

28 State Street, 7th Floor, Boston, Massachusetts 02109
(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS

(57) Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor.

WO 2021/211860 A1